Dermata Therapeutics Inc
NASDAQ:DRMA
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.82
14.2
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Dermata Therapeutics Inc
NASDAQ:DRMA
|
2.4m USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
982.2B USD |
Loading...
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
526.1B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
276.2B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
215.4B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
221.7B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.7B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.7T DKK |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
145.8B USD |
Loading...
|
Market Distribution
Other Profitability Ratios
Dermata Therapeutics Inc
Glance View
Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. The company is headquartered in San Diego, California and currently employs 8 full-time employees. The company went IPO on 2021-08-13. The firm focuses on the treatment of medical and aesthetic skin conditions. Its lead product candidate, DMT310, is a product candidate, which is developed from its Spongilla technology platform. DMT310 is a topical product derived from sourced freshwater sponge with multiple components. Its DMT310 is under clinical development for the treatment of acne vulgaris (acne), psoriasis vulgaris (psoriasis), and papulopustular rosacea (rosacea). The Company’s Spongilla technology platform is based on the use of a naturally growing freshwater sponge, Spongilla lacustris (Spongilla). Spongilla is a freshwater sponge that grows in rivers and lakes in commercial quantities in select regions of the world, such as the northern hemisphere. Its clinical development pipeline consists of DMT310 and DMT410.